Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026
Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026
Company Deals

Bayer and JD Health Collaborate on Dulcolax-Lactulose to Expand China’s Digestive-Health Market

Fineline Cube Jul 21, 2025

Bayer (ETR: BAYN) and JD Health (HKG: 6618) have launched Dulcolax-branded lactulose in a pioneering...

Company Drug

Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension

Fineline Cube Jul 21, 2025

US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500...

Company Deals

VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies

Fineline Cube Jul 21, 2025

VivaVision Biotech recently announced the successful closing of its D2+ funding round, raising 140 million...

Company Drug

Youcare Pharma Subsidiary Gains NMPA Clearance for Phase I Study of siRNA Hypertension Drug YKYY029

Fineline Cube Jul 18, 2025

China-based Youcare Pharma (SHA: 688658) announced that its subsidiary Youcare InnoTech and partner Hangzhou Tianlong...

Company Drug

GSK’s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma

Fineline Cube Jul 18, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the US Food and Drug Administration (FDA) Oncologic...

Company Deals

Robo Medical Secures Tens of Millions in Funding for EndoFaster and EndoDreams Development

Fineline Cube Jul 18, 2025

China-based Robo Medical Technology Co. has closed a strategic funding round amounting to “tens of...

Company Drug

CanSino Bio Receives NMPA Approval for Phase I/II Trial of Recombinant Polio Vaccine

Fineline Cube Jul 18, 2025

China-based CanSino Biologics Inc., (HKG: 6185) announced that it and its subsidiary CanSino (Shanghai) Biotechnology...

Company Drug

Yifan Pharma’s Generic Glycerol Phenylbutyrate Accepted for NMPA Review

Fineline Cube Jul 18, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that the National Medical Products Administration (NMPA)...

Company Drug

Hengrui Pharmaceuticals’ SHR-8068 Gains NMPA Approval for NSCLC and Colorectal Cancer Trials

Fineline Cube Jul 18, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical...

Company Drug

Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004

Fineline Cube Jul 18, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao...

Company Drug

Legend Biotech’s Carvykti Achieves USD 439 Million in Q2 2025 Sales

Fineline Cube Jul 18, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) reported that sales of Carvykti reached USD 439 million...

Company Deals

Buchang Pharma Subsidiary Establishes Shaanxi Buchang MedData with Lingyishushu

Fineline Cube Jul 18, 2025

Shandong Buchang Chuanfang, a subsidiary of China-based Buchang Pharma (SHA: 603858), announced the establishment of...

Company

Novartis Reports Double-Digit Growth in Q2 and 1H25, Driven by Key Brands

Fineline Cube Jul 17, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) reported double-digit growth in both revenue and net income...

Company Drug

Takeda’s Oveporexton Meets All Endpoints in Phase 3 Narcolepsy Type 1 Trials

Fineline Cube Jul 17, 2025

Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that both Phase 3 randomized, double-blind, placebo-controlled...

Company Deals

PHASE Scientific Partners with Lumos Diagnostics to Launch FebriDx in US Respiratory Market

Fineline Cube Jul 17, 2025

China-based PHASE Scientific has entered into an exclusive distribution agreement with Lumos Diagnostics to introduce...

Company Drug

Daiichi Sankyo and AstraZeneca Submit Enhertu Application for HER2-Positive Gastric Cancer in China

Fineline Cube Jul 17, 2025

Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have submitted a supplemental new-drug application...

Company

Johnson & Johnson Reports 5.8% Sales Growth in 2025Q2, Increases Full-Year Guidance

Fineline Cube Jul 17, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced its second-quarter 2025 (2025Q2) results, reporting...

Company Policy / Regulatory

Konruns’ KC1036 Proposed for CDE’s SPARK Program to Accelerate Pediatric Ewing’s Sarcoma Treatment Development

Fineline Cube Jul 17, 2025

Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced on Wednesday that China’s Center for Drug...

Company Drug

Hainan Boao Research Hospital Secures Approval for China’s First Medical-Food Import for Rare Metabolic Disorders

Fineline Cube Jul 17, 2025

Hainan Boao Research Hospital, operated by Shanghai’s Ruijin Hospital, has obtained provincial approval to import...

Company Drug

Sanofi’s Gene Therapy SAR446597 Secures FDA Fast Track for Geographic Atrophy

Fineline Cube Jul 17, 2025

France-based Sanofi (NASDAQ: SNY) announced that its one-time intravitreal gene therapy SAR446597 has received FDA...

Posts pagination

1 … 139 140 141 … 679

Recent updates

  • PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset
  • Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence
  • Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
  • Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Company Medical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.